Incyte (INCY) Misses Q1 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 falls from record high as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Incyte (INCY) Price Target Lifted to $107 at Brean Capital; 'Broad And Robust Pipeline'
April 30, 2015 12:34 PM EDTBrean Capital analyst Jonathan Aschoff reiterated a Buy rating and boosted his price target on Incyte (NASDAQ: INCY) to $107.00 (from $84.00), citing a broad and robust pipeline.
Aschoff commented, "US Jakafi sales of $115.3 million included meaningful contribution from PV and beat consensus of $112.4 million. Ex-US Jakafi royalties of $15.7 million slightly missed consensus of $16.1 million. The 9% QoQ increase in Jakafi net sales was driven by 8% unit... More
Incyte's (INCY) Hodgkin Lymphoma Treatment Receives FDAOrphan Drug Designation
April 30, 2015 9:07 AM EDTIncyte (NASDAQ: INCY) received orphan drug Designation for treatment of Hodgkin lymphoma. The FDA site on the designation is here.
... More